OrsoBio Revenue and Competitors
Estimated Revenue & Valuation
- OrsoBio's estimated annual revenue is currently $1M per year.
- OrsoBio's estimated revenue per employee is $77,500
Employee Data
- OrsoBio has 13 Employees.
- OrsoBio grew their employee count by 8% last year.
OrsoBio's People
Name | Title | Email/Phone |
---|---|---|
1 | Co-Founder, Board Member, Chief Business Officer | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Chief Medical Officer and Head Development | Reveal Email/Phone |
4 | Chief Medical Officer and Head Development | Reveal Email/Phone |
5 | VP, Clinical Development & Operations | Reveal Email/Phone |
6 | VP Product Development and Program Management | Reveal Email/Phone |
7 | Director, Regulatory Affairs | Reveal Email/Phone |
8 | Scientist | Reveal Email/Phone |
OrsoBio Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is OrsoBio?
OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat severe metabolic disorders, including type 2 diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism.
keywords:N/AN/A
Total Funding
13
Number of Employees
$1M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.7M | 13 | -7% | N/A |
#2 | $2M | 13 | 8% | N/A |
#3 | $1.1M | 13 | 18% | N/A |
#4 | $1M | 13 | N/A | N/A |
#5 | $1.2M | 13 | -19% | N/A |